AXSM Stock In Spotlight Ahead Of Key FDA Verdict On Alzheimer’s Drug This Week
Axsome Therapeutics (AXSM) is awaiting a crucial FDA decision on its Alzheimer's agitation treatment, AXS-05, with a Prescription Drug User Fee Act (PDUFA) target action date of April 30, 2026. The drug, which targets symptoms like distress and aggressive behavior in Alzheimer's patients, has patents extending to at least 2043 and has already seen its stock rise by nearly 15% in the last month. Retail sentiment remains bullish ahead of the verdict, with some investors anticipating a significant stock increase upon approval.
Axsome Therapeutics (AXSM) Stock Still Trades Below Fair Value On Sales
Axsome Therapeutics (AXSM) stock has seen significant gains over five years but current valuations suggest it trades below its fair value based on sales. While the company's P/S ratio of 14.7x is higher than the industry average, Simply Wall St's fair P/S ratio is 17.4x, indicating it might be undervalued. The investment case hinges on Axsome's ability to convert its pipeline into durable cash flows, despite execution risks in research and commercialization.
Lisanti Capital Growth LLC Acquires Shares of 20,825 Axsome Therapeutics, Inc. $AXSM
Lisanti Capital Growth LLC acquired a new position of 20,825 shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) valued at approximately $5.1 million during the second quarter. This move is part of broader institutional investment, with BlackRock also establishing a significant new position, bringing total institutional ownership to 81.49%. Despite the company missing recent earnings and revenue estimates, analysts maintain a "Moderate Buy" consensus rating with an average price target of $267.60.
Eagle Health Investments LP Invests $15.92 Million in Axsome Therapeutics, Inc. $AXSM
Eagle Health Investments LP has acquired a new position in Axsome Therapeutics, purchasing 65,051 shares valued at approximately $15.92 million, making it their 15th biggest position. Other institutional investors like BlackRock Inc., Price T Rowe Associates Inc. MD, Wellington Management Group LLP, Invesco Ltd., and Geode Capital Management LLC have also significantly invested in Axsome Therapeutics, with institutional investors and hedge funds owning 81.49% of the company's stock. Despite recent insider selling and a Q2 earnings miss, analysts generally maintain a "Moderate Buy" rating with an average target price of $267.60, indicating a positive outlook for the company's future.
Enterprise value to EBITDA forward of Axsome Therapeutics, Inc. – SWB:19X
This article provides the enterprise value to EBITDA forward for Axsome Therapeutics, Inc. (SWB:19X) on the Stuttgart Stock Exchange. It highlights the financial metric without further detailed analysis or commentary. The page is from TradingView, offering an overview of financial data for the company.
Here’s How Much You Would Have Made Owning Axsome Therapeutics Stock In The Last 5 Years
Axsome Therapeutics (NASDAQ: AXSM) has significantly outperformed the market over the last five years, with an average annual return of 58.59%. An investment of $100 in AXSM five years ago would now be worth $1,086.24, highlighting the power of compounded returns. The company currently has a market capitalization of $11.32 billion.
Pallas Capital Advisors LLC Acquires Shares of 40,511 Axsome Therapeutics, Inc. $AXSM
Pallas Capital Advisors LLC has acquired 40,511 shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) for approximately $9.9 million, adding to institutional ownership which collectively stands at 81.49%. Despite Axsome missing quarterly earnings and revenue estimates, analysts maintain a "Moderate Buy" rating with a consensus price target of $267.60, even as insiders have sold significant shares. The company focuses on developing therapies for central nervous system disorders.
TimesSquare Capital Management LLC Takes Position in Axsome Therapeutics, Inc. $AXSM
TimesSquare Capital Management LLC has acquired 71,510 shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) valued at approximately $17.5 million during the second quarter, making them a new institutional investor in the company. Despite Axsome Therapeutics missing its Q2 earnings and revenue estimates, analysts maintain a "Moderate Buy" rating with an average price target significantly above its current trading price. Insider activity shows recent stock sales by a director and the CEO, while institutional investors collectively own a substantial portion of the company's stock.
Axsome Therapeutics (AXSM) After Mixed Earnings What Does The Valuation Narrative Say
Axsome Therapeutics (AXSM) recently reported mixed Q2 2026 earnings, with increased revenue but wider net losses, causing a slight share price dip. Despite the recent pullback, the stock shows strong long-term momentum, with a 92.3% one-year total shareholder return. While analysts value AXSM as 24.4% undervalued at $282.51 per share, driven by its late-stage CNS pipeline, its current P/S ratio of 14.4x is higher than the industry average and raises valuation risk concerns.
Axsome Therapeutics (AXSM) After Mixed Earnings What Does The Valuation Narrative Say
Axsome Therapeutics (AXSM) is under scrutiny after reporting mixed Q2 2026 earnings, with increased revenue but also wider net losses. Despite a recent pullback, the stock shows strong long-term momentum, and analysts currently value it at $282.51 per share, suggesting it is undervalued compared to its recent close of $213.67. This valuation is driven by its late-stage clinical programs and potential for diversified revenue, though the company faces risks from ongoing losses and reliance on key products.
OneDigital Investment Advisors LLC Makes New Investment in Axsome Therapeutics, Inc. $AXSM
OneDigital Investment Advisors LLC has invested in Axsome Therapeutics, purchasing 7,787 shares valued at approximately $1.9 million during the second quarter. Despite Axsome Therapeutics missing its Q2 earnings and revenue estimates and recent insider selling, analysts maintain a "Moderate Buy" rating with an average price target of $267.60. Institutional investors now own 81.49% of the company's stock.
Axsome Therapeutics, Inc. (AXSM) Stock Analysis: Significant 33.58% Upside Potential with Strong Buy Ratings
Axsome Therapeutics (AXSM) is a biotechnology company focused on CNS disorders with a strong market capitalization of $11.19 billion. Analysts project a 33.58% upside potential with an average target price of $285.42 and a consensus of 20 buy ratings, driven by impressive revenue growth despite current negative earnings. The company's portfolio includes commercial products like Auvelity and Sunosi, alongside a promising pipeline, making it an attractive option for investors with a high-risk tolerance seeking biotech exposure.
GSA Capital Partners LLP Makes New $2.31 Million Investment in Axsome Therapeutics, Inc. $AXSM
GSA Capital Partners LLP initiated a new $2.31 million position in Axsome Therapeutics, Inc. ($AXSM) during the second quarter of 2026 by acquiring 9,419 shares. This investment comes despite Axsome missing analyst estimates for both revenue and EPS in its latest earnings report, and significant insider selling, including a $7.9 million sale by CFO Nick Pizzie. Institutional investors now collectively own 81.49% of the company, and analysts maintain a "Moderate Buy" consensus rating with an average price target of $267.60.
If You Invested $100 In Axsome Therapeutics Stock 10 Years Ago, You Would Have This Much Today
Axsome Therapeutics (NASDAQ: AXSM) has significantly outperformed the market over the last 10 years, achieving an average annual return of 40.19%. An initial investment of $100 in AXSM stock a decade ago would now be worth $2,919.13, highlighting the power of compounded returns. The company currently holds a market capitalization of $11.19 billion.
Handelsbanken Fonder AB Has $10.38 Million Stock Position in Axsome Therapeutics, Inc. $AXSM
Handelsbanken Fonder AB significantly increased its stake in Axsome Therapeutics, Inc. by 216.4% in the second quarter, now holding 42,400 shares valued at $10.38 million. This comes despite Axsome Therapeutics missing analyst expectations for both earnings and revenue in its latest quarterly report. The company maintains a "Moderate Buy" consensus rating from analysts with an average price target of $267.60.
AXSOME THERAPEUTICS, INC. : MIZUHO RAISES TARGET PRICE TO $316 FROM $306
Mizuho has increased its target price for Axsome Therapeutics, Inc. to $316, up from the previous $306. This adjustment indicates a positive outlook from the analyst firm regarding the biopharmaceutical company's future performance.
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Axsome Therapeutics, Inc. reported second-quarter revenues that met expectations, but statutory losses per share were higher than anticipated. While analysts reconfirmed revenue forecasts for 2026, they significantly expanded per-share loss estimates, yet the consensus price target remained unchanged. The company is still projected to grow substantially faster than its industry, with revenue growth in line with its past five-year performance.
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Axsome Therapeutics reported Q2 revenues of US$218m, meeting expectations, but statutory losses per share were higher at US$0.99. Analysts reconfirmed revenue forecasts for 2026 at US$972.9m, a 25% increase, but expanded per-share loss expectations to US$2.62. Despite the mixed outlook, the consensus price target remains at US$285, indicating analysts believe the business is performing as expected.
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Consensus Rating of "Moderate Buy" by Brokerages
Axsome Therapeutics (NASDAQ:AXSM) has received a consensus "Moderate Buy" rating from 22 brokerages, with an average 12-month price target of $267.60, significantly above its current trading price of $214.66. This comes despite the company missing its latest quarterly earnings expectations, reporting a wider loss and lower revenue than anticipated. Insider selling was also notable during the quarter, with CEO Herriot Tabuteau selling a substantial number of shares.
Mizuho raises Axsome Therapeutics stock price target on Auvelity
Mizuho increased its price target for Axsome Therapeutics (NASDAQ:AXSM) to $316 from $306, maintaining an Outperform rating due to positive expectations for Auvelity's launch in Alzheimer’s disease agitation, increased operating leverage, and strong commercial execution. This comes after the company reported a 57% revenue growth in the last twelve months, despite a Q2 2026 revenue miss and a wider-than-expected loss per share. Other analysts like RBC Capital, Needham, Guggenheim, and Wells Fargo have offered mixed but generally optimistic outlooks, adjusting their price targets based on Auvelity's performance and future potential.
UBS Adjusts Price Target on Axsome Therapeutics to $280 From $259, Keeps Buy Rating
UBS has increased its price target for Axsome Therapeutics (AXSM) to $280 from $259, while maintaining a Buy rating on the stock. This adjustment suggests a positive outlook from UBS on the pharmaceutical company's future performance.
UBS Adjusts Price Target on Axsome Therapeutics to $280 From $259, Keeps Buy Rating
UBS has increased its price target for Axsome Therapeutics (NASDAQ: AXSM) to $280 from $259, while maintaining a Buy rating on the stock. This adjustment reflects UBS's continued positive outlook on the biopharmaceutical company. Separately, Mizuho also adjusted its price target for Axsome Therapeutics to $316 from $306, keeping an Outperform rating.
Quantinno Capital Management LP Acquires 5,019 Shares of Axsome Therapeutics, Inc. $AXSM
Quantinno Capital Management LP increased its stake in Axsome Therapeutics (NASDAQ:AXSM) by 77.5% in the first quarter, purchasing an additional 5,019 shares and bringing its total holdings to 11,497 shares valued at $1.94 million. Despite revenue growth driven by Auvelity sales, Axsome Therapeutics missed Q2 earnings and revenue estimates, reporting a loss of $0.99 per share. Analysts maintain a "Moderate Buy" rating with an average price target of $267.10, although concerns about valuation and profitability persist.
Axsome Therapeutics (AXSM) Stock Faces Revenue Momentum And Lingering Losses
Axsome Therapeutics (AXSM) reported Q2 revenue of US$218.4m, driven by its neurology brands, but also posted a net loss of US$51.3m, causing a slight stock pullback. While revenue growth is strong, particularly from AUVELITY, concerns remain about profitability due to high gross-to-net discounts, rising SG&A expenses, and continued cash burn. The market is evaluating whether the company's revenue engine can overcome these lingering losses and reach profitability.
AXSOME THERAPEUTICS, INC. : MORGAN STANLEY RAISES TARGET PRICE TO $251 FROM $242
Morgan Stanley has increased its target price for Axsome Therapeutics, Inc. (AXSM) to $251 from $242. This update reflects an analyst's revised valuation for the company. The article, sourced from Reuters, provides this key financial adjustment.
Faster Revenue Growth With Wider Losses Might Change The Case For Investing In Axsome (AXSM)
Axsome Therapeutics, Inc. reported increased revenue in Q2 2026 but also widened net losses, driven by expanding its CNS portfolio and commercialization efforts. While revenue growth is strong, the growing net loss and cash burn raise concerns for investors regarding the company's ability to offset these losses with future product revenue. The article suggests that despite strong top-line growth, the persistent losses and cash needed for ongoing launches remain the biggest near-term risk.
Axsome Therapeutics shares gain 2% as strong sales growth offsets Q2 miss
Axsome Therapeutics (NASDAQ:AXSM) shares rose 2.09% in pre-market trading despite missing Q2 earnings and revenue expectations, as investors focused on robust underlying product growth. The company reported a wider loss of $0.99 per share and revenue of $218.4 million, but sales surged 46% year-over-year, driven by strong performance from AUVELITY and the initial momentum of its Alzheimer's disease agitation launch. Increased commercial spending for AUVELITY and SYMBRAVO contributed to the net loss.
Axsome Therapeutics Inc earnings missed by $0.14, revenue fell short of estimates
Axsome Therapeutics Inc (NASDAQ: AXSM) reported its second-quarter earnings, missing analyst estimates for both EPS and revenue. The company posted an EPS of $-0.99 against an estimated $-0.85, and revenue of $218.37M fell short of the $221.92M consensus. Despite the recent miss, the stock has shown significant growth over the last 12 months, increasing by 104.64%.
Earnings Flash (AXSM) Axsome Therapeutics, Inc. Reports Q2 Revenue $218.4M, vs. FactSet Est of $221.1M
Axsome Therapeutics, Inc. (AXSM) reported its Q2 revenue at $218.4 million, falling short of the FactSet estimate of $221.1 million. The company's stock was trading at $219.19 USD with a 3.03% change on August 10, 2026. This earnings flash was published at 07:21 am EDT on August 10, 2026.
Axsome Therapeutics (NASDAQ: AXSM) Q2 revenue jumps 46% as CNS pipeline advances
Axsome Therapeutics reported strong Q2 2026 revenue growth, with total net product revenue increasing 46% year-over-year to $218.4 million, driven by AUVELITY, SUNOSI, and SYMBRAVO sales. Despite this growth, the company posted a net loss of $51.3 million due to higher SG&A expenses from expanded commercialization activities, including the AUVELITY launch for Alzheimer's agitation. Axsome also highlighted significant pipeline advancements, including FDA acceptance for AXS-12 in narcolepsy and ongoing Phase 3 trials for solriamfetol in ADHD, binge eating disorder, and shift work disorder, affirming its focus on CNS disorders.
Axsome Reports 126% More AUVELITY Starts Among 65+ Patients in 8 Weeks
Axsome Therapeutics announced strong financial results for Q2 2026, with total net product revenue increasing 46% year-over-year to $218.4 million, driven by significant growth in sales of AUVELITY, SUNOSI, and SYMBRAVO. The company reported a net loss of $51.3 million but indicated that current cash reserves of $319.9 million are sufficient to fund operations until cash flow positivity. Axsome also highlighted key pipeline progress, including the FDA acceptance of the NDA for AXS-12 and the initiation of multiple Phase 3 trials for solriamfetol.
Hennion & Walsh Asset Management Inc. Sells 19,128 Shares of Axsome Therapeutics, Inc. $AXSM
Hennion & Walsh Asset Management Inc. significantly reduced its stake in Axsome Therapeutics by selling 19,128 shares, lowering their holdings to 17,505 shares valued at $4.29 million. This sale follows similar actions by Axsome's CFO and CEO, who collectively sold shares worth approximately $19.9 million in June, contributing to a total of $46.7 million in insider sales over 90 days. Despite this insider selling, institutional ownership remains high at 81.49%, and analysts maintain a "Moderate Buy" rating with a consensus price target of $265.55 against the current $212.74 stock price.
Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Axsome Therapeutics reported strong second-quarter 2026 financial results, with total net product revenue reaching $218.4 million, a 46% year-over-year increase, driven by significant growth in AUVELITY sales. The company also provided a business update highlighting the launch of AUVELITY for agitation associated with Alzheimer’s disease, FDA acceptance of the AXS-12 NDA for narcolepsy, and the initiation of Phase 3 trials for solriamfetol in pediatric ADHD. Axsome anticipates continued commercial momentum and pipeline advancements, projecting sufficient cash to fund operations into cash flow positivity.
Axsome Therapeutics (AXSM) Could Be 25% Undervalued As CNS Pipeline Hopes Build
Axsome Therapeutics (AXSM) is considered 25% undervalued with a fair value of $282.51, despite a recent 9% stock decline. The valuation is driven by its expanding CNS portfolio, late-stage clinical programs, and projected rapid revenue growth and margin improvements. However, the company faces risks related to product concentration and ongoing net losses.
How Axsome Therapeutics Inc. (AXSM) Affects Rotational Strategy Timing
Axsome Therapeutics Inc. (AXSM) is analyzed through institutional trading strategies by Stock Traders Daily. The report identifies weak near and mid-term sentiment but a strong long-term outlook for AXSM, highlighting specific entry, target, and stop-loss points for position, momentum, and risk-hedging strategies. AI-generated signals provide support and resistance levels across various time horizons, indicating potential challenges for the long-term positive outlook due to current weak sentiment.
AXSOME THERAPEUTICS Q2 2026 Earnings Preview: Recent $AXSM Insider Trading, Hedge Fund Activity, and More
AXSOME THERAPEUTICS ($AXSM) is set to release its Q2 2026 earnings on August 10th, with analysts projecting revenues of $225.45 million and an EPS of -$0.86. The article details recent insider trading activity, showing 16 sales and zero purchases over the last six months by executives. It also highlights significant hedge fund movements, with some institutions dramatically increasing or decreasing their holdings, and provides recent analyst price targets with a median of $263.5.
Assenagon Asset Management S.A. Cuts Stock Holdings in Axsome Therapeutics, Inc. $AXSM
Assenagon Asset Management S.A. significantly reduced its stake in Axsome Therapeutics, Inc. by 47.5% in the second quarter, selling over 411,000 shares but still retaining a substantial holding valued at $111.3 million. Despite this, institutional investors collectively own 81.49% of the company, and analyst sentiment remains positive with a "Moderate Buy" consensus and an average price target of $265.55. Insider selling activity was also noted, with two directors recently decreasing their holdings.
Axsome Therapeutics, Inc. $AXSM Shares Sold by Bank of America Corp DE
Bank of America Corp DE reduced its stake in Axsome Therapeutics by 3.2% in the first quarter, selling 19,942 shares and retaining 598,091 shares worth $101.1 million. Despite mixed analyst ratings, the company holds a "Moderate Buy" consensus with a $265.55 price target. Over the last three months, company insiders sold 200,766 shares valued at $46.7 million, primarily to cover tax obligations from equity awards.
Axsome therapeutics CEO Herriot Tabuteau sells $10.5m in shares
Axsome Therapeutics CEO Herriot Tabuteau sold approximately $10.5 million worth of common stock on August 5 and 6, 2026, following the exercise of stock options that were nearing their expiration date. These transactions were executed under a pre-approved 10b5-1 trading plan. Despite the sales, Tabuteau retains a significant indirect beneficial ownership in the company, which has seen a 103% gain over the past year and recently had its New Drug Application for AXS-12 accepted by the FDA.
Axsome Therapeutics (AXSM) Stock Looks Near Fair Value Despite Premium Sales Pricing
Axsome Therapeutics (AXSM) stock appears to be priced near its fair value, despite its premium sales pricing, following a significant 5-year gain and a recent pullback. The company's P/S ratio of 15.3x is higher than industry averages but aligns closely with its estimated fair P/S ratio of 16.6x. The valuation now presents a balanced risk-reward profile, with future performance dependent on the company's ability to convert its pipeline into consistent, high-quality cash flow.
AXSM (AXSM) holder files to sell 4,660 shares via cashless option exercise
A holder of Axsome Therapeutics (AXSM) has filed a Form 144 to sell 4,660 common shares through a cashless option exercise, valued at approximately $979,205.80. These shares, acquired in 2017 as compensation via stock options, are intended for sale on or after August 6, 2026. The filing also details several prior sales by Herriot Tabuteau in the preceding three months, ranging from $4.26 million to $6.02 million.
Axsome Therapeutics (AXSM) insider plans 45,004-share cashless option sale
Axsome Therapeutics insider Herriot Tabuteau has filed a Form 144 indicating an intention to sell up to 45,004 shares of common stock through Goldman Sachs & Co. LLC, with an approximate sale date of August 5, 2026. The shares were originally acquired as compensation via stock options on March 15, 2017, and the transaction is structured as a cashless exercise/same-day sale. This filing also notes previous sales by Tabuteau in June and July 2026, and provides context with the total shares outstanding for Axsome Therapeutics (AXSM).
Axsome Therapeutics Inc (AXSM) News, Articles, Events & Latest Updates
This article provides a compilation of recent news, articles, and updates related to Axsome Therapeutics Inc (AXSM), focusing on its upcoming Q2 earnings, FDA approvals, and ongoing clinical trials. It also includes several Zacks reports placing AXSM on a "Strong Sell" list. Additionally, it highlights Axsome's specialization in central nervous system disorders.
Is Axsome Therapeutics (AXSM) Trading Profitability for Pipeline Expansion As Revenue Outpaces Earnings?
Axsome Therapeutics (AXSM) is projected to report higher Q2 2026 revenue but lower year-over-year earnings, leading to investor scrutiny regarding its profitability amidst pipeline expansion. The company's investment narrative centers on its CNS franchise eventually translating rising revenues into sustainable profitability, with an FDA acceptance for AXS 12 in narcolepsy (PDUFA date May 2027) supporting its long-term growth strategy. Despite revenue momentum, concerns about rising SG&A and persistent losses remain key factors for investors evaluating the company's risk-reward profile.
Axsome Therapeutics (NASDAQ:AXSM) Stock Price Down 4% After Analyst Downgrade
Axsome Therapeutics (NASDAQ:AXSM) shares dropped 4% after Mizuho lowered its price target from $310 to $306, while still maintaining an "outperform" rating. Despite missing adjusted earnings expectations with a loss of $1.26 per share, the company reported a 57.4% year-over-year revenue increase to $191.2 million. Analyst sentiment remains largely positive, holding a "Moderate Buy" consensus with an average price target of $261.29.
Axsome Therapeutics, Inc. (AXSM): Investor Outlook on a Biotech Stock with a 29% Potential Upside
Axsome Therapeutics (AXSM) is a biotech company focused on CNS disorders with a market capitalization of $11.22 billion. Despite negative EPS and ROE, the company has strong analyst ratings, an average target price suggesting a 29.51% upside, and robust revenue growth of 57.40%. Its product portfolio and pipeline, including Auvelity and Sunosi, indicate significant growth potential for long-term investors with high-risk tolerance.
Axsome Therapeutics (AXSM) to Announce Earnings on Monday
Axsome Therapeutics (NASDAQ: AXSM) is scheduled to announce its Q2 2026 earnings before the market opens on Monday, August 10th. Analysts anticipate a loss of $0.8921 per share and revenue of $221.1 million. Despite a previous EPS miss, revenue increased by 57.4% year-over-year, and analysts maintain a "Moderate Buy" rating with an average price target of $261.29, though significant insider selling has occurred.
Axsome Therapeutics Inc (0HKF) Q3 2025 Earnings Report - Results, Call & Slides
Axsome Therapeutics (0HKF) released its Q3 2025 earnings report, missing consensus EPS estimates with an actual EPS of -$0.94 against an expected -$0.86. However, the company beat revenue expectations, reporting $170.99M against an expected $162.67M, marking a significant 63.22% year-over-year revenue growth. The earnings call took place on November 3, 2025, and the next earnings date is estimated for August 10, 2026.
Axsome Therapeutics, Inc. $AXSM Stock Holdings Lessened by The Manufacturers Life Insurance Company
The Manufacturers Life Insurance Company reduced its stake in Axsome Therapeutics (NASDAQ:AXSM) by 12.5% in the first quarter, selling 16,791 shares. Despite this, institutional investors collectively own 81.49% of the company, with many major funds increasing their positions. Axsome Therapeutics reported revenue of $191.2 million, up 57.4% year over year, but missed analyst EPS estimates with a loss of $1.26 per share.
Axsome Therapeutics Inc (0HKF) Q3 2024 Earnings Report - Results, Call & Slides
Axsome Therapeutics Inc (0HKF) has released its Q3 2024 earnings report, detailing actual EPS of -$1.34 which beat the consensus of -$1.38, and actual revenue of $104.76M, exceeding the expected $98.37M with an 81.27% year-over-year growth. The report includes an audio recording of the earnings call and a slide deck. The company's next earnings date is estimated for August 10, 2026.
